Baker Bros. Advisors LP Madrigal Pharmaceuticals, Inc. Transaction History
Baker Bros. Advisors LP
- $12.3 Billion
- Q3 2025
A detailed history of Baker Bros. Advisors LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,141,701 shares of MDGL stock, worth $1.13 Billion. This represents 8.0% of its overall portfolio holdings.
Number of Shares
2,141,701
Previous 1,976,018
8.38%
Holding current value
$1.13 Billion
Previous $598 Million
64.26%
% of portfolio
8.0%
Previous 6.06%
Shares
10 transactions
Others Institutions Holding MDGL
# of Institutions
405Shares Held
23.1MCall Options Held
666KPut Options Held
514K-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.81MShares$959 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...